<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361060</url>
  </required_header>
  <id_info>
    <org_study_id>PRIN-SUGAR-2014</org_study_id>
    <nct_id>NCT02361060</nct_id>
  </id_info>
  <brief_title>Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery</brief_title>
  <official_title>Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enrique Alday Muñoz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary complications are relatively frequent after surgery, and can be associated with an
      increase in morbidity and mortality. Although there are several causative mechanisms that can
      lead to postoperative pulmonary complications, alterations in the shape and motion of the
      chest wall are of primary importance.

      In the investigator´s institution the incidence of postoperatory hypoxemia defined as
      pO2/FiO2 &lt;300 is over 20% for patients after major abdominal surgery.

      Observational and randomized clinical trials have demonstrated that incomplete neuromuscular
      recovery during the early postoperative period may result in acute respiratory events
      (hypoxemia and airway obstruction) and an increased risk of postoperative pulmonary
      complications.

      A recent study in laparoscopic bariatric surgery showed that patients in which neuromuscular
      block reversal was done with sugammadex had less chest X-ray pathological changes than those
      from an historical cohort reversed with neostigmine.

      The hypothesis is that differences in pulmonary complications, as atelectasis and hypoxemia,
      between patients reverted with sugammadex or neostigmine may be more apparent with more
      sensitive techniques like spirometry or lung ultrasound when they exist.

      Lung ultrasound (LUS) has demonstrated a sensitivity of 90% and a specificity of 98%, to
      detect alveolar consolidation in critical ill patients while chest radiography data are known
      to be imprecise.The investigator would like to explore the utility of LUS in postsurgical
      patients and the relationship between degree of hypoxemia and consolidation area.

      Objectives:

        1. Primary: Forced vital capacity decreases after surgery. This reduction may be relieved
           in the absence of residual neuromuscular block. Objective is to assess differences after
           reversal with neostigmine versus sugammadex in:

           • Forced vital capacity (FVC)

        2. Secondary objectives: To assess differences after reversal with neostigmine versus
           sugammadex in:

             -  Atelectasis size determined by lung ultrasound (Plannimetry)

             -  pO2/FiO2 &lt;300 1 hour after surgery

             -  Explore the accuracy of lung ultrasound (LUS) to diagnosis postoperative
                atelectasis and its correlation with chest Xray, FVC and pO2/FiO2.

      Hypotheses:

        1. Sugammadex NMB reversal results in a lower reduction of forced vital capacity (FVC) as
           compared to NMB reversal with neostigmine.

        2. Atelectasis is common after major surgery. Size of atelectasis determined by lung
           ultrasound planimetry is lower one hour after sugammadex reversal as compared to the
           neostigmine group.

        3. The incidence of post-surgical hypoxemia is lower in the sugammadex group as compared to
           the neostigmine group (Hypoxemia defined as pO2/FiO2 less than 300 is expected in 20% of
           patients after major abdominal surgery).

        4. Lung ultrasound has a better capacity to detect alveolar consolidation than Chest Xray
           after major surgery.

        5. Atelectasis size determine by planimetry has a good correlation with pO2/FiO2 and
           decrease of FVC after surgery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 4, 2016</completion_date>
  <primary_completion_date type="Actual">July 4, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in FVC at 1h after surgery</measure>
    <time_frame>Basal and one hour after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atelectasis size determined by lung ultrasound (Plannimetry)</measure>
    <time_frame>One hour after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atelectasis size determined by lung ultrasound (Plannimetry)</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pO2/FiO2 &lt;300</measure>
    <time_frame>1 hour after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asociation between atelectasis size and FVC</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>Atelectasis size (sqr cm) will me measured by planimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asociation between atelectasis size and FVC</measure>
    <time_frame>24 hour after surgery</time_frame>
    <description>Atelectasis size (sqr cm) will me measured by planimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asociation between atelectasis size and pO2/FiO2</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>Atelectasis size (sqr cm) will me measured by planimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asociation between atelectasis size and pO2/FiO2</measure>
    <time_frame>24 hour after surgery</time_frame>
    <description>Atelectasis size (sqr cm) will me measured by planimetry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Major Abdominal Surgery</condition>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sugammadex 4 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine + Atropine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neostigmine 40µg/kg in combination with atropine 10µg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>40mcg/kg</description>
    <arm_group_label>Neostigmine + Atropine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>4mg/kg</description>
    <arm_group_label>Sugammadex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine</intervention_name>
    <description>10 mcg/kg</description>
    <arm_group_label>Neostigmine + Atropine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Every patient scheduled for major abdominal surgery (liver resection, pancreatectomy,
             gastrectomy or any type of colectomy) will be nominated to participate in the study.

          -  Informed consent will be asked for after their admission to the hospital the day
             before the surgery.

          -  Patients with postoperative epidural analgesia.

        Exclusion Criteria:

          -  Refusal to participate.

          -  Entry to postoperative recovery unit under mechanical ventilation.

          -  Hypersensitivity reactions to any of the drugs.

          -  Severe asthma and mild asthma under treatment.

          -  Myocardial infarction or coronary occlusion three months prior to surgery.

          -  Myasthenia gravis.

          -  Emergency surgery.

          -  Pulmonary fibrosis or very severe chronic obstructive lung disease (GOLD IV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anesthesiology Service. Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.1016/j.redar.2014.02.005</url>
    <description>Sugammadex and anaphylaxis in the operating theater.</description>
  </link>
  <link>
    <url>http://dx.doi.org/10.1016/j.redar.2013.11.009</url>
    <description>Postoperative respiratory outcomes in laparoscopic bariatric surgery: Comparison of a prospective group of patients whose neuromuscular blockade was reverted with sugammadex and a his-torical one reverted with neostigmine</description>
  </link>
  <link>
    <url>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000885/WC500052310.pdf</url>
    <description>labbel information Bridion®. European Agency for the Evaluation of Medicinal Products (EMEA). Acceso: octubre 2009.</description>
  </link>
  <link>
    <url>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000885/WC500052309.pdf</url>
    <description>European Public Assessment Report for Bridion®. London: European Agency for the Evaluation ofMedicinal Products (EMEA), Committee for Propietary Medicinal Products (CPMP).</description>
  </link>
  <reference>
    <citation>Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, Giunta FG, Meistelman C, Prins ME. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008 May;100(5):622-30. doi: 10.1093/bja/aen037. Epub 2008 Apr 2.</citation>
    <PMID>18385265</PMID>
  </reference>
  <reference>
    <citation>Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008 Nov;109(5):816-24. doi: 10.1097/ALN.0b013e31818a3fee.</citation>
    <PMID>18946293</PMID>
  </reference>
  <reference>
    <citation>Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology. 2009 May;110(5):1020-5. doi: 10.1097/ALN.0b013e31819dabb0.</citation>
    <PMID>19387176</PMID>
  </reference>
  <reference>
    <citation>Staals LM, Snoeck MM, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth. 2008 Oct;101(4):492-7. doi: 10.1093/bja/aen216. Epub 2008 Jul 23.</citation>
    <PMID>18653492</PMID>
  </reference>
  <reference>
    <citation>Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009 Oct;26(10):874-84. doi: 10.1097/EJA.0b013e32832c605b.</citation>
    <PMID>19455040</PMID>
  </reference>
  <reference>
    <citation>Yang LP, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs. 2009;69(7):919-42. doi: 10.2165/00003495-200969070-00008. Review.</citation>
    <PMID>19441874</PMID>
  </reference>
  <reference>
    <citation>Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007362. doi: 10.1002/14651858.CD007362.pub2. Review.</citation>
    <PMID>19821409</PMID>
  </reference>
  <reference>
    <citation>Ferreyra G, Long Y, Ranieri VM. Respiratory complications after major surgery. Curr Opin Crit Care. 2009 Aug;15(4):342-8. doi: 10.1097/MCC.0b013e32832e0669. Review.</citation>
    <PMID>19542885</PMID>
  </reference>
  <reference>
    <citation>Squadrone V, Coha M, Cerutti E, Schellino MM, Biolino P, Occella P, Belloni G, Vilianis G, Fiore G, Cavallo F, Ranieri VM; Piedmont Intensive Care Units Network (PICUN). Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial. JAMA. 2005 Feb 2;293(5):589-95.</citation>
    <PMID>15687314</PMID>
  </reference>
  <reference>
    <citation>Yu CJ, Yang PC, Wu HD, Chang DB, Kuo SH, Luh KT. Ultrasound study in unilateral hemithorax opacification. Image comparison with computed tomography. Am Rev Respir Dis. 1993 Feb;147(2):430-4.</citation>
    <PMID>8430970</PMID>
  </reference>
  <reference>
    <citation>Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010 Jul;111(1):120-8. doi: 10.1213/ANE.0b013e3181da832d. Epub 2010 May 4. Review.</citation>
    <PMID>20442260</PMID>
  </reference>
  <reference>
    <citation>Tusman G, Böhm SH, Warner DO, Sprung J. Atelectasis and perioperative pulmonary complications in high-risk patients. Curr Opin Anaesthesiol. 2012 Feb;25(1):1-10. doi: 10.1097/ACO.0b013e32834dd1eb. Review.</citation>
    <PMID>22113182</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</investigator_affiliation>
    <investigator_full_name>Enrique Alday Muñoz</investigator_full_name>
    <investigator_title>Principal investigator.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

